The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5
The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5
复制标题
非布索坦与别嘌呤醇对中国无症状高尿酸血症和慢性肾脏病 3-5 期患者的降尿酸疗效和安全性
DOI：
10.1007/s10157-018-1652-5
复制
发表时间：
2019-03-01
影响因子：
2.3
通讯作者：
Xu, Yan
中科院分区：
文献类型：
--
作者：
Liu, Xuemei;Wang, Huifang;Xu, Yan
虽然别嘌呤醇在慢性肾脏疾病（CKD）患者中的剂量有限，但关于非布司他在中国高尿酸血症和CKD 3-5期患者中的疗效、安全性和维持剂量的信息缺乏。方法采用单中心、前瞻性队列研究，对尚未开始接受肾脏替代治疗的3-5期CKD伴高尿酸血症患者进行研究。在这项研究中，我们招募了208名新接受非布司他（n=112）或别嘌呤醇（n=96）治疗的患者。非布司他的疗效以血清尿酸（sUA）患者的比例来衡量。
BackgroundWhile the dose of allopurinol is limited in patients with chronic kidney disease (CKD), information is lacking concerning the efficacy, safety, and maintenance dose of febuxostat in Chinese patients with hyperuricemia and with CKD stages 3-5.MethodsA single center, prospective cohort study was conducted in patients with CKD stages 3-5 and with hyperuricemia who had not yet begun to undergo renal replacement therapy. We enrolled 208 patients who were newly treated with febuxostat (n=112) or allopurinol (n=96) in this study. The efficacy of febuxostat was determined by the proportion of patients with serum uric acid (sUA)